OptimUM-01
88 evidence topics · 12 sources
Objective
First-line cohort: safety and efficacy of darovasertib plus crizotinib in the phase 2 expansion
Registry title and purpose of the basket study
HLA-A∗02:01-positive expansion: analysis of participants treated with darovasertib plus crizotinib
First-line and pretreated cohorts: evaluation of the combination
Location and study date
Registry study dates
| Study characteristic | Quoted record |
|---|---|
| Study start (actual) | “2019-06-28” |
| Primary completion (estimated) | “2027-01-29” |
| Study completion (estimated) | “2027-06-15” |
Registry study sites
| Country | Quoted site |
|---|---|
| United States | “UCLA Medical Center” |
| United States | “San Francisco Oncology Associates” |
| United States | “SCRI - Denver” |
| United States | “University of Iowa” |
| United States | “Cancer Hematology Centers Western Michigan” |
| United States | “Columbia University Medical Center - Herbert Irving Pavilion” |
| United States | “Duke University Medical Center” |
| United States | “University of Cincinnati Cancer Center” |
| United States | “The Cleveland Clinic Foundation” |
| United States | “Sidney Kimmel Cancer Center at Thomas Jefferson University” |
| United States | “The Sarah Cannon Research Institute/Tennessee Oncology” |
| United States | “The University of Texas MD Anderson Cancer Center” |
| Australia | “Westmead Hospital” |
| Canada | “Princess Margaret Cancer Centre” |
First-line cohort publication: enrolling centers
First-line cohort: data cutoff of May 28, 2025
HLA-A∗02:01-positive expansion: data extract date of March 23, 2026
First-line and pretreated cohorts: data cutoff of August 22, 2023
Study design
First-line cohort: phase 1/2, multicenter, open-label, dose-escalation and expansion design
Registry design: nonrandomized, open-label, sequential assignment
| Study characteristic | Quoted record |
|---|---|
| Other study ID number | “IDE196-001” |
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Sequential Assignment” |
| Masking | “None (Open Label)” |
Registry: crizotinib combination dose optimization, crizotinib monotherapy cohort, and enrollment status by cohort
Registry: enrolling crizotinib combination expansion cohort of HLA-A∗02:01-positive participants with nested pharmacokinetic substudies
Combination dose escalation: 3 + 3 design followed by expansion
HLA-A∗02:01-positive expansion: study design as described in the poster
Eligibility criteria
Inclusion criteria, including documentation required for treatment-naive HLA-A∗02:01-positive participants
Additional inclusion criteria for the crizotinib combination
Additional exclusion criteria for the crizotinib combination
Registry: exclusion criteria of the pravastatin pharmacokinetic substudy
HLA-A∗02:01-positive expansion: eligibility criteria
First-line and pretreated cohorts: eligibility criteria
Treatment
First-line cohort: dose selection, darovasertib run-in, and continuous 28-day cycles
Registry interventions: oral twice-daily dosing in 28-day cycles
First-line and pretreated cohorts: expansion dose of darovasertib 300 mg and crizotinib 200 mg twice a day
Selection of the combination expansion dose for potential registrational studies
Study outcomes
Rationale for using RECIST v1.1 objective response rate as the primary endpoint
First-line cohort: investigator-assessed RECIST v1.1 response and imaging schedule
First-line cohort: end points, with overall survival as an exploratory end point
First-line cohort: definitions of objective response, disease control, and duration of response
First-line cohort: definitions of progression-free survival, overall survival, and molecular response
Registry primary outcomes
Registry secondary outcomes
FDA guidance: objective response rate as a direct measure of antitumor activity evaluable in a single-arm study
FDA guidance: single-arm studies, accelerated approval, and time-to-event end points
IDE196 monotherapy: FDA End-of-Phase 1 feedback on a single-arm design with response rate as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
First-line cohort: 44 participants enrolled and treated, 41 evaluable for response
Registry: estimated enrollment
| Study characteristic | Quoted record |
|---|---|
| Enrollment (estimated), all cohorts of the basket study | “336” |
Pretreated cohort, data cutoff of November 25, 2021: target enrollment of the combination arm and participants enrolled at the expansion dose
First-line and pretreated cohorts, data cutoff of March 8, 2023: safety population of 68 and per-protocol efficacy population of 63 participants
HLA-A∗02:01-positive expansion: 101 participants treated
Description of analysis sets
First-line cohort: safety population and efficacy-evaluable population
First-line cohort: three participants excluded from the response analysis
First-line cohort: descriptive analysis without formal hypothesis testing
First-line cohort: censoring rules for progression-free survival
HLA-A∗02:01-positive expansion: efficacy-evaluable population and all-enrolled population
Results
Participant disposition
First-line cohort: discontinuations due to treatment-emergent adverse events
HLA-A∗02:01-positive expansion: discontinuations due to adverse events
First-line and pretreated cohorts, data cutoff of August 22, 2023: duration of treatment and participants continuing treatment
Baseline characteristics
First-line cohort: baseline characteristics of 44 participants
| Characteristic | First-line cohort, N = 44 |
|---|---|
| Age, median years (range) | “64.5 (21, 80)” |
| Age less than 65 years, No. (%) | “22 (50.0)” |
| Female, No. (%) | “21 (47.7)” |
| Male, No. (%) | “23 (52.3)” |
| Race White, No. (%) | “41 (93.2%)” |
| Race Asian, No. (%) | “1 (2.3%)” |
| Race other or not reported, No. (%) | “2 (4.5%)” |
| ECOG PS 0, No. (%) | “27 (61.4)” |
| ECOG PS 1, No. (%) | “17 (38.6)” |
| Baseline LDH normal, No. (%) | “29 (65.9)” |
| Baseline LDH above ULN, No. (%) | “14 (31.8)” |
| Baseline LDH more than 2× ULN, No. (%) | “7 (15.9)” |
| Largest metastatic lesion 3.0 cm or less, No. (%) | “24 (54.5)” |
| Largest metastatic lesion 3.1 to 8.0 cm, No. (%) | “15 (34.1)” |
| Largest metastatic lesion 8.1 cm or more, No. (%) | “4 (9.1)” |
| Metastases hepatic only, No. (%) | “23 (52.3)” |
| Metastases extrahepatic only, No. (%) | “2 (4.5)” |
| Metastases hepatic and extrahepatic, No. (%) | “18 (40.9)” |
| HLA-A∗02:01 negative, No. (%) | “30 (68.2)” |
| HLA-A∗02:01 positive, No. (%) | “12 (27.3)” |
| HLA-A∗02:01 unknown, No. (%) | “2 (4.5)” |
First-line cohort: high-risk features and HLA testing at enrollment
First-line cohort: performance status compared by the sponsor with an earlier registrational study
HLA-A∗02:01-positive expansion: baseline characteristics of treatment-naive and overall populations
| Characteristic | Treatment-naive, N = 13 | Overall, N = 101 |
|---|---|---|
| Age, median years (range) | “65.0 (21, 81)” | “66.0 (21, 81)” |
| Female, n (%) | “7 (53.8)” | “44 (43.6)” |
| Race White, n (%) | “13 (100.0)” | “95 (94.1)” |
| ECOG PS 0, n (%) | “6 (46.2)” | “66 (65.3)” |
| ECOG PS 1, n (%) | “7 (53.8)” | “35 (34.7)” |
| Baseline LDH at or below ULN, n (%) | “7 (53.8)” | “36 (35.6)” |
| Baseline LDH above ULN and below 2× ULN, n (%) | “4 (30.8)” | “43 (42.6)” |
| Baseline LDH 2× ULN or higher, n (%) | “2 (15.4)” | “22 (21.8)” |
| Metastases hepatic only, n (%) | “8 (61.5)” | “51 (50.5)” |
| Metastases extrahepatic only, n (%) | “2 (15.4)” | “12 (11.9)” |
| Metastases hepatic and extrahepatic, n (%) | “3 (23.1)” | “38 (37.6)” |
| No prior lines of therapy, n (%) | “13 (100)” | “13 (12.9)” |
| Prior lines of therapy | Overall, N = 101, n (%) |
|---|---|
| One prior line of therapy | “20 (19.8)” |
| Two or more prior lines of therapy | “67 (66.3)” |
| Not recorded, previously treated | “1 (1.0)” |
HLA-A∗02:01-positive expansion: prior systemic therapy, including second-line treatment after tebentafusp
First-line and pretreated cohorts, per-protocol efficacy population: tumor burden and HLA-A∗02:01 status
Efficacy results
First-line cohort, efficacy-evaluable population of 41 participants: response, duration of response, and disease control
| Outcome | First-line cohort, N = 41 |
|---|---|
| Objective response rate, No. (%) | “14 (34.1)” |
| Objective response rate, 95% CI | “20.1 to 50.6” |
| Best overall response CR, No. (%) | “0 (0.0)” |
| Best overall response PR, No. (%) | “14 (34.1)” |
| Best overall response SD, No. (%) | “23 (56.1)” |
| Best overall response PD, No. (%) | “4 (9.8)” |
| Duration of response, median months | “9.0” |
| Duration of response, 95% CI | “3.8 to 12.0” |
| Time to response, median months | “2.0” |
| Disease control rate at 8 weeks, No. (%) | “37 (90.2)” |
| Disease control rate at 8 weeks, 95% CI | “76.9 to 97.3” |
| Disease control rate at 26 weeks, No. (%) | “22 (53.7)” |
| Disease control rate at 26 weeks, 95% CI | “37.4 to 69.3” |
First-line cohort: tumor shrinkage
First-line cohort, safety population: progression-free survival and overall survival at a median follow-up of 25 months
First-line cohort: progression-free survival and overall survival with confidence intervals as stated in the abstract
First-line cohort: confirmed response by HLA-A∗02:01 status
| Outcome | HLA-A∗02:01 positive, n = 10 | HLA-A∗02:01 negative, n = 29 |
|---|---|---|
| Objective response rate, No. (%) | “3 (30.0)” | “9 (31.0)” |
| Objective response rate, 95% CI | “3.7 to 65.2” | “15.3 to 50.8” |
| Best overall response PR, No. (%) | “3 (30.0)” | “9 (31.0)” |
| Best overall response SD, No. (%) | “7 (70.0)” | “16 (55.2)” |
| Best overall response PD, No. (%) | “0 (0.0)” | “4 (13.8)” |
| Disease control rate, No. (%) | “10 (100.0)” | “25 (86.2)” |
| Disease control rate, 95% CI | “NA” | “68.3 to 96.1” |
| Duration of response, median months | “10.15” | “9.03” |
| Duration of response, 95% CI | “3.75 to NE” | “1.94 to 9.03” |
| Time to response, median months | “3.7” | “1.9” |
First-line cohort: response in HLA-A∗02:01-positive participants as stated in the discussion
First-line cohort: response by baseline LDH
| Outcome | LDH at or below ULN, n = 28 | LDH above ULN to 2× ULN, n = 7 | LDH above 2× ULN, n = 6 |
|---|---|---|---|
| Objective response rate, No. (%) | “8 (28.6)” | “2 (28.6)” | “4 (66.7)” |
| Objective response rate, 95% CI | “13.2 to 48.7” | “3.7 to 71.0” | “22.3 to 95.7” |
| Best overall response SD, No. (%) | “17 (60.7)” | “4 (57.1)” | “2 (33.3)” |
| Best overall response PD, No. (%) | “3 (10.7)” | “1 (14.3)” | “0 (0.0)” |
| Disease control rate, No. (%) | “25 (89.3)” | “6 (85.7)” | “6 (100)” |
First-line cohort: response by tumor burden (largest metastatic lesion)
| Outcome | 3 cm or less, n = 23 | Above 3 cm to 8 cm, n = 15 | Above 8 cm, n = 3 |
|---|---|---|---|
| Objective response rate, No. (%) | “9 (39.1)” | “4 (26.7)” | “1 (33.3)” |
| Objective response rate, 95% CI | “19.7 to .61.5” | “7.8 to 55.1” | “0.8 to 90.6” |
| Best overall response SD, No. (%) | “14 (60.9)” | “7 (46.7)” | “2 (66.7)” |
| Best overall response PD, No. (%) | “0 (0.0)” | “4 (26.7)” | “0 (0.0)” |
| Disease control rate, No. (%) | “23 (100.0)” | “11 (73.3)” | “3 (100.0)” |
First-line cohort: molecular response in circulating cell-free DNA
HLA-A∗02:01-positive expansion: response, progression-free survival, and overall survival in treatment-naive and overall populations
| Outcome | Treatment-naive, N = 13 | Overall, N = 101 |
|---|---|---|
| Objective response rate, n/N (%) | “4/11 (36.4)” | “19/86 (22.1)” |
| Objective response rate, 95% CI | “10.9, 69.2” | “13.9, 32.3” |
| Confirmed best overall response CR, n/N (%) | “0/11 (0.0)” | “0/86 ( 0.0)” |
| Confirmed best overall response SD, n/N (%) | “6/11 (54.5)” | “49/86 (57.0)” |
| Confirmed best overall response PD, n/N (%) | “0/11 (0.0)” | “9/86 (10.5)” |
| Confirmed best overall response not evaluable, n/N (%) | “1/11 (9.1)” | “9/86 (10.5)” |
| Disease control rate, n/N (%) | “10/11 (90.9)” | “69/86 (80.2)” |
| Median progression-free survival, 95% CI | “3.6, 19.6” | “3.7, 6.8” |
| Median overall survival, 95% CI | “8.9, NE” | “9.8, 26.3” |
HLA-A∗02:01-positive expansion: second-line participants after tebentafusp
| Outcome | Prior tebentafusp (second line), N = 15 |
|---|---|
| Objective response rate, n/N | “(5/14)” |
| Objective response rate, 95% CI | “12.8-64.9” |
| Disease control rate, % | “85.7%” |
| Disease control rate, n/N | “(12/14)” |
| Median duration of response | “5.6 mos” |
| Median progression-free survival, 95% CI | “3.65-NE” |
| Median overall survival, 95% CI | “9.79-NE” |
HLA-A∗02:01-negative participants of OptimUM-01 as reported for comparison in the HLA-A∗02:01-positive expansion poster
| Outcome | HLA-A∗02:01 negative, treatment-naive, N = 29 | HLA-A∗02:01 negative, overall, N = 61 |
|---|---|---|
| Objective response rate, n/N (%) | “9/29 (31.0)” | “16/61 (26.2)” |
| Objective response rate, 95% CI | “15.3, 50.8” | “15.8, 39.1” |
| Disease control rate, n/N (%) | “25/29 (86.2)” | “53/61 (86.9)” |
| Median progression-free survival, 95% CI | “3.7, 9.2” | “5.0, 7.8” |
| Median overall survival, 95% CI | “12.0, 23.8” | “11.7, 20.7” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
First-line cohort: dose intensity
First-line cohort: treatment-emergent adverse event summary
| Adverse event | All grades, No. (%) | Grade 3 or higher, No. (%) |
|---|---|---|
| Any AE | “44 (100)” | “23 (52.3)” |
| Serious AE | “9 (20.5)” | “8 (18.2)” |
| AE leading to discontinuation | “3 (6.8)” | “1 (2.3)” |
| AEs related to darovasertib leading to reduction | “3 (6.8)” | “0” |
| AEs related to crizotinib leading to reduction | “4 (9.1)” | “1 (2.3)” |
| Diarrhea | “42 (95.5)” | “1 (2.3)” |
| Nausea | “37 (84.1)” | “0” |
| Edema peripheral | “27 (61.4)” | “0” |
| Vomiting | “23 (52.3)” | “0” |
| Dermatitis acneiform | “20 (45.5)” | “0” |
| Hypoalbuminemia | “19 (43.2)” | “1 (2.3)” |
| Fatigue | “18 (40.9)” | “0” |
| Constipation | “13 (29.5)” | “1 (2.3)” |
| Dizziness | “13 (29.5)” | “1 (2.3)” |
| Decreased appetite | “11 (25.0)” | “0” |
| Alanine aminotransferase increased | “9 (20.5)” | “2 (4.5)” |
| Headache | “9 (20.5)” | “0” |
| Aspartate aminotransferase increased | “8 (18.2)” | “1 (2.3)” |
| Cough | “8 (18.2)” | “0” |
| Dyspnea | “8 (18.2)” | “0” |
| Hypophosphatemia | “8 (18.2)” | “0” |
| Hypotension | “8 (18.2)” | “1 (2.3)” |
| Anemia | “7 (15.9)” | “0” |
| Blood alkaline phosphatase increased | “7 (15.9)” | “0” |
| Dysgeusia | “7 (15.9)” | “0” |
| Blood creatinine increased | “6 (13.6)” | “0” |
| COVID-19 | “6 (13.6)” | “0” |
| Generalized edema | “6 (13.6)” | “1 (2.3)” |
| Hypokalemia | “6 (13.6)” | “2 (4.5)” |
| Pruritus | “6 (13.6)” | “0” |
| Rash maculopapular | “6 (13.6)” | “0” |
| Vision blurred | “6 (13.6)” | “2 (4.5)” |
| Blood lactate dehydrogenase increased | “5 (11.4)” | “0” |
| Cancer fatigue | “5 (11.4)” | “0” |
| Face edema | “5 (11.4)” | “0” |
| Gastroesophageal reflux disease | “5 (11.4)” | “0” |
| Iron deficiency anemia | “5 (11.4)” | “3 (6.8)” |
| Periorbital edema | “5 (11.4)” | “0” |
First-line cohort: most common adverse events, grade 3 or higher events, serious adverse events, and deaths
First-line cohort: most common adverse events as stated in the abstract
First-line cohort: treatment-related adverse event summary
| Adverse event | All grades, No. (%) | Grade 3 or higher, No. (%) |
|---|---|---|
| Treatment-related AE | “43 (97.7)” | “12 (27.3)” |
| Treatment-related serious AE | “4 (9.1)” | “3 (6.8)” |
| Treatment-related AE leading to discontinuation | “2 (4.5)” | “1 (2.3)” |
| Diarrhea | “40 (90.9)” | “1 (2.3)” |
| Nausea | “35 (79.5)” | “0” |
| Edema peripheral | “27 (61.4)” | “0” |
| Vomiting | “21 (47.7)” | “0” |
| Dermatitis acneiform | “19 (43.2)” | “0” |
| Hypoalbuminemia | “19 (43.2)” | “1 (2.3)” |
| Fatigue | “17 (38.6)” | “0” |
| Dizziness | “12 (27.3)” | “1 (2.3)” |
| Decreased appetite | “8 (18.2)” | “0” |
| Hypotension | “8 (18.2)” | “1 (2.3)” |
| Constipation | “7 (15.9)” | “0” |
| Aspartate aminotransferase increased | “6 (13.6)” | “0” |
| Dysgeusia | “6 (13.6)” | “0” |
| Rash maculopapular | “6 (13.6)” | “0” |
| Alanine aminotransferase increased | “5 (11.4)” | “1 (2.3)” |
| Anemia | “5 (11.4)” | “0” |
| Blood alkaline phosphatase increased | “5 (11.4)” | “0” |
| Face edema | “5 (11.4)” | “0” |
| Generalized edema | “5 (11.4)” | “0” |
| Hypophosphatemia | “5 (11.4)” | “0” |
| Periorbital edema | “5 (11.4)” | “0” |
| Pruritus | “5 (11.4)” | “0” |
First-line cohort: treatment-emergent serious adverse events
| Serious adverse event | Overall population, N = 44, No. (%) |
|---|---|
| Any serious adverse event | “9 (20.5)” |
| Ascites | “1 (2.3)” |
| Bacteremia | “1 (2.3)” |
| Cancer pain | “1 (2.3)” |
| Cholecystitis | “1 (2.3)” |
| Diarrhea | “1 (2.3)” |
| Fall | “1 (2.3)” |
| Generalized edema | “1 (2.3)” |
| Pulmonary embolism (listed in two rows of the source table) | “1 (2.3)” |
| Pancreatitis acute | “1 (2.3)” |
| Sudden death | “1 (2.3)” |
First-line cohort: hypotension, the most common dose-limiting toxicity of darovasertib monotherapy
First-line cohort: overlapping toxicities of the two agents
HLA-A∗02:01-positive expansion, overall population: treatment-related adverse events
| Adverse event | Overall, N = 101, n (%) |
|---|---|
| Related adverse event | “101 (100)” |
| Related serious adverse event | “12 (11.9)” |
| Related grade 3 or higher adverse event | “38 (37.6)” |
| Related adverse event leading to discontinuation | “9 (8.9)” |
| Related adverse events leading to reduction | “28 (27.7)” |
| Diarrhea | “83 ( 82.2)” |
| Nausea | “77 ( 76.2)” |
| Edema peripheral | “71 ( 70.3)” |
| Vomiting | “58 ( 57.4)” |
| Fatigue | “55 ( 54.5)” |
| Dizziness | “38 ( 37.6)” |
| Dermatitis acneiform | “35 ( 34.7)” |
| Hypotension | “33 ( 32.7)” |
First-line and pretreated cohorts at the expansion dose, safety population: drug-related adverse events
First-line and pretreated cohorts, 68 participants: drug-related adverse events and serious adverse events
Pretreated cohort, 22 participants: drug-related adverse events
Study limitations
Summary
The OptimUM-01 first-line cohort is an open-label, single-arm, nonrandomized expansion of 44 participants, of whom 41 were efficacy-evaluable; the authors describe the data as hypothesis-generating. No formal hypothesis testing was prespecified, and all results were summarized descriptively. Response was assessed by the investigator per RECIST version 1.1. The efficacy-evaluable population required at least one post-baseline tumor assessment, which excluded two participants who discontinued before assessment (one for sudden death) and one ongoing participant; PFS and OS were measured from the first day of treatment in the safety population, and OS is an exploratory end point. The authors state that PFS and OS results are preliminary and that the proportion censored and the medians will change with longer follow-up. Disease control was defined as stable disease lasting at least 8 weeks, where OptimUM-02 required at least 12 weeks. The HLA-A∗02:01 subgroups comprise 29 HLA-A∗02:01-negative and 10 HLA-A∗02:01-positive evaluable participants, and HLA status was unknown for about 5% because testing was not routinely performed at enrollment. Molecular response could be assessed in only the 20 participants with driver mutations reported from tumor tissue. The study reports no quality-of-life or patient-reported outcome results; its end points were safety, ORR, duration of response, disease control rate, PFS, and OS. Comparisons with historical data sets carry, in the authors' words, “the necessary caveats and limitations of cross-study comparisons”.
In the HLA-A∗02:01-positive expansion, response was assessed in an efficacy-evaluable population of participants with at least 3 post-baseline assessments or who discontinued treatment, giving denominators of 11 of 13 treatment-naive and 86 of 101 overall participants. IDEAYA's earlier phase 2 results for 68 participants receiving the combination (data cutoff August 22, 2023) were preliminary and based on investigator review from an unlocked database.
Within the first-line cohort publication, the 95% CIs for median PFS (3.8 to 7.7 months in the results; 5.0 to 8.3 months in the abstract) and median OS (12.5 to 27.1 months; 11.9 to 20.7 months) differ, as do the ORR in HLA-A∗02:01-positive participants (30.0%, 3 of 10, in the subgroup table; 40% in the discussion), the incidence of diarrhea (95.5%; 95.2%), and the incidence of hypotension (18.3%; 18.2%).